0000899243-22-003083.txt : 20220124
0000899243-22-003083.hdr.sgml : 20220124
20220124212721
ACCESSION NUMBER: 0000899243-22-003083
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220120
FILED AS OF DATE: 20220124
DATE AS OF CHANGE: 20220124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ENLOE J DAVID JR
CENTRAL INDEX KEY: 0001201526
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36329
FILM NUMBER: 22550956
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Recro Pharma, Inc.
CENTRAL INDEX KEY: 0001588972
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261523233
STATE OF INCORPORATION: PA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 E. UWCHLAN AVE, SUITE 112
CITY: EXTON
STATE: PA
ZIP: 19341
BUSINESS PHONE: 770-534-8239
MAIL ADDRESS:
STREET 1: 1 E. UWCHLAN AVE, SUITE 112
CITY: EXTON
STATE: PA
ZIP: 19341
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-20
0
0001588972
Recro Pharma, Inc.
REPH
0001201526
ENLOE J DAVID JR
C/O RECRO PHARMA, INC.
1 E. UWCHLAN AVE, SUITE 112
EXTON
PA
19341
1
1
0
0
Chief Executive Officer
Common Stock
2022-01-20
4
A
0
66007
A
220766
D
Common Stock
2022-01-20
4
A
0
303030
0.00
A
523796
D
Stock Option (Right to Buy)
1.65
2022-01-20
4
A
0
442478
0.00
A
2032-01-20
Common Stock
442478
442478
D
On January 20, 2022, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 66,007 performance-based restricted stock units granted in a prior year, which were converted into 66,007 shares of common stock on a one-for-one basis.
These restricted stock units will vest in four equal annual installments beginning on January 20, 2023, subject to continued service with the Company.
The stock option vests in equal monthly installments over 48 months, beginning on February 20, 2022, subject to continued service with the Company.
By: Ryan D Lake, attorney-in-fact
2022-01-24